Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.